Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use
|
|
- Justin Evans
- 8 years ago
- Views:
Transcription
1 25 April 2014 EMA/237058/2014 Procedure Management and Business Support Division Applications for new human under evaluation by the Committee for Medicinal Products for Human Use April 2014 This document lists information on applications for centralised marketing authorisation for human that the European Medicines Agency has received for evaluation. It includes the international non-proprietary names (INN) and therapeutic areas for all new innovative under evaluation by the Committee for Medicinal Products for Human Use (CHMP). For generic and biosimilar, it includes the INN (active moiety only, with no information on salt, ester or derivative) and therapeutic area. This list only includes information for whose applications have been validated at the time the report was compiled. The information in this report was compiled on 14 April Information on designated orphan that are being assessed for marketing authorisation is also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP). Information in bold corresponds to new entries in the monthly list. Entries are removed from this list once the medicine has received a positive or negative opinion from the CHMP or when the applicant has withdrawn the application. The Agency publishes information on these opinions and withdrawn applications on its website. Information on CHMP opinions is also published in the monthly CHMP highlights. 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom Telephone +44 (0) Facsimile +44 (0) info@ema.europa.eu Website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.
2 Non-orphan medicinal products International non-proprietary name (salt, ester, derivative, etc.) / Aclidinium (bromide) / formoterol fumarate (dihydrate) Apremilast Balugrastim Bazedoxifene (acetate) / estrogens conjugated Brinzolamide / brimonidine (tartrate) Cangrelor Ceritinib Ciclosporin Clopidogrel (bisulfate) / acetylsalicylic acid Daclatasvir (dihydrochloride) Dalbavancin (hydrochloride) Darunavir (ethanolate) / cobicistat Dolutegravir / abacavir / lamivudine Dulaglutide Edoxaban (tosylate) Faldaprevir Ferric citrate coordination complex Flutemetamol (18F) Guanfacine (hydrochloride) Human alpha1-proteinase inhibitor Human fibrinogen / human thrombin Human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) Idelalisib Insulin degludec / liraglutide Lamivudine (hydrate) / raltegravir (potassium) Liraglutide Therapeutic area 1 Medicines for obstructive airway diseases Immunosuppressants Sex hormones and modulators of the genital system Antithrombotic Antithrombotic Antibacterials for Antithrombotic Other therapeutic Antihypertensives Vaccines 1 Based on the ATC therapeutic sub-group. Applications for new human under evaluation by the Committee for Medicinal Products for Human Use EMA/237058/2014 Page 2/5
3 International non-proprietary name (salt, ester, derivative, etc.) / Lutetium (177 Lu) (chloride) Mixture of polynuclear iron(iii)-oxyhydroxide, sucrose and starches Naloxegol (oxalate) Naltrexone (hydrochloride) / bupropion (hydrochloride) Netupitant / palonosetron (hydrochloride) Nintedanib Nonacog gamma Oritavancin (diphosphate) Ospemifene Peginterferon beta-1a Perflubutane Phenylephrine (hydrochloride) / ketorolac (trometamol) Safinamide (methanesulfonate) Secukinumab Simoctocog alfa Sofosbuvir / ledipasvir Spheroids of human autologous matrixassociated chondrocytes Tedizolid (phosphate) Tilmanocept Trametinib Vorapaxar Therapeutic area 1 Other therapeutic Medicines for constipation Antiobesity Antiemetics and antinauseants Antibacterials for Sex hormones and modulators of the genital system Contrast media Anti-parkinson Immunosuppressants Other for disorders of the musculo-skeletal system Antibacterials for Antithrombotic Applications for new human under evaluation by the Committee for Medicinal Products for Human Use EMA/237058/2014 Page 3/5
4 Non-orphan generic and biosimilar medicinal products International non-proprietary name / Therapeutic area 2 Total number of applications Budesonide / formoterol Medicines for obstructive 3 airway diseases Busulfan 1 Insulin glargine 1 Tacrolimus Immunosuppressants 1 Tadalafil Urologicals 1 Voriconazole Antimycotics for 1 Orphan medicinal products International nonproprietary name (salt, ester, derivative, etc.) / Product name Marketing authorisation applicant Therapeutic area 3 Afamelanotide Scenesse Clinuvel (UK) Limited Emollients and protectives Allogeneic T cells genetically modified to Zalmoxis MolMed SpA express suicide gene Allogenic human heterologous liver cells Heparesc Cytonet GmbH&Co KG Other alimentary tract and metabolism products Dasiprotimut-t Dasiprotim Biovest Europe Ltd ut-t Biovest Dexamethasone (acetate) Neofordex Laboratoires Ctrs - Boulogne Billancourt Corticosteroids for Dinutuximab Unituxin United Therapeutics Europe Ltd Eliglustat Cerdelga Genzyme Europe BV Other alimentary tract and metabolism products 2 Based on the ATC therapeutic sub-group. 3 Based on the ATC therapeutic sub-group. Applications for new human under evaluation by the Committee for Medicinal Products for Human Use EMA/237058/2014 Page 4/5
5 International nonproprietary name (salt, ester, derivative, etc.) / Product name Marketing authorisation applicant Therapeutic area 3 Ex vivo autologous corneal Holoclar Chiesi Farmaceutici S.p.A. epithelial cells including stem cells Ibrutinib Imbruvica Janssen-Cilag International NV Ketoconazole Ketoconaz ole aidscfm Agenzia Industrie Difesa- Stabilimento Chimico Other therapeutic Farmaceutico Militare Ketoconazole Ketoconaz ole lab hra Laboratoire HRA Pharma Antimycotics for pharma Levofloxacin Levofloxaci n Aptalis Aptalis Pharma SAS Antibacterials for Mifepristone Corluxin FGK Representative Service GmbH Systemic hormonal preparations, excl. sex hormones and insulins Obinutuzumab Gazyva Roche Registration Ltd Olaparib Olaparib AstraZenec AstraZeneca AB a AB Ramucirumab Cyramza Eli Lilly Nederland B.V. Recombinant l-asparaginase Spectrila medac Gesellschaft fuer klinische Spezialpraeparate mbh Tobramycin Vantobra PARI Pharma GmbH Antibacterials for Tolvaptan Jinarc Otsuka Pharmaceutical Europe Ltd Urologicals Applications for new human under evaluation by the Committee for Medicinal Products for Human Use EMA/237058/2014 Page 5/5
Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use
23 June 206 EMA/40396/206 - corr Information Management Division Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use June 206 This document lists
More informationCommittee for Orphan Medicinal Products (COMP)
11 October 2010 EMA/COMP/586816/2010 Human Medicines Development and Evaluation Monthly report 6-7 October 2010 The Committee for Orphan Medicinal Products held its 116 th plenary meeting on 6-7 October
More informationmeeting report on the review of applications for orphan designation
13 June 2014 EMA/COMP/309595/2014 Committee for Orphan Medicinal Products (COMP) Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation June
More informationATC/DDD Classification
ATC/DDD Classification ATC/DDD Classification (Temporary) The following ATC codes, DDDs and alterations were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology
More informationEU Clinical Trials Register. www.clinicaltrialsregister.eu. An agency of the European Union
EU Clinical Trials Register www.clinicaltrialsregister.eu An agency of the European Union The EU Clinical Trials Register provides public access to information from the European Union (EU) clinical trial
More informationRegulatory approval routes in the European System for Medicinal Products
Regulatory approval routes in the European System for Medicinal Products Cardiovascular Combination Pharmacotherapy Global Summit, Melbourne, 8 th May 2014 Presented by: Kevin Blake Human Medicines Research
More informationSpecialty Pipeline Update
CLINICAL SOLUTIONS Drug Insights > June 2014 Specialty Pipeline Update New Drug Information Eloctate (recombinant factor VIII Fc fusion protein): Biogen received FDA approval for their hemophilia A for
More informationIn non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:
EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human
More informationICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS
More informationDraft agreed by the QWP February 2015. Draft adopted by the CHMP for release for consultation March 2015. Draft endorsed by the CMD(h) March 2015
1 2 3 26 March 2015 EMA/CHMP/QWP/104223/2015 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Reflection paper on the chemical structure and properties criteria to be considered for the evaluation
More informationStandard operating procedure
Standard operating procedure Title: Review and revision of effective work instructions Status: PUBLIC Document no.: SOP/EMA/0034 Approver Effective date: 10-Jul-13 Name: Mario Benetti Name: Guido Rasi
More informationDraft agreed by the QWP February 2015. Draft adopted by the CHMP for release for consultation March 2015. Draft endorsed by the CMD(h) March 2015
17 December 2015 EMA/CHMP/QWP/104223/2015 Committee for Medicinal Products for Human Use (CHMP) Reflection paper on the chemical structure and properties criteria to be considered for the evaluation of
More informationWork instructions. 1. Changes since last revision. 2. Records. 3. Instructions. Title: How to create reports from scientific memory database (SMD)
Work instructions Title: How to create reports from scientific memory database (SMD) Applies to: Clinical and Non-Clinical Compliance Section Status: PUBLIC Document no.: WIN/INSP/2040 Lead Author Approver
More informationQuestions and answers on post approval change management protocols
27 October 2010 EMA/CHMP/CVMP/QWP/586330/2010 Questions and answers on post approval change management protocols Draft Draft Agreed by QWP September 2010 Adoption by CHMP for release for consultation 23
More informationList of nationally authorised medicinal products
9 July 2015 EMA/483660/2015 Procedure Management and Committees Support Active substance: diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated), haemophilus type b conjugate
More informationSevere rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.
EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human
More informationEuropean Medicines Agency decision
EMA/650134/2010 European Medicines Agency decision P/202/2010 of 27 October 2010 on the acceptance of a modification of an agreed paediatric investigation plan for propranolol hydrochloride, (EMEA-000511-PIP01-08-M02)
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS
European Medicines Agency Evaluation of Medicines for Human Use CHMP/437/04 London, 30 October 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS
More informationAdoption by CHMP for release for consultation November 2010. End of consultation (deadline for comments) 31 March 2011
1 2 3 November 2010 EMA/759784/2010 Committee for Medicinal Products for Human Use 4 5 6 7 Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and
More informationAll the steps detailed in this WIN are carried out by the assistant in the Sampling and Testing Team in the MQC Section.
Work instructions Title: Sampling and testing of centrally authorised products - update of spreadsheet for the identification of the products to be tested on the basis of a risk assessment Applies to:
More informationEMA esignature capabilities: frequently asked questions relating to practical and technical aspects of the implementation
August 2013 EMA/264709/2013 EMA esignature capabilities: frequently asked questions relating to practical and technical aspects of the implementation This question and answer document aims to address the
More informationGuideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)
22 May 2014 EMA/CHMP/BWP/247713/2012 Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:
More informationQuestions and answers on post approval change management protocols
30 March 2012 EMA/CHMP/CVMP/QWP/586330/2010 Committee for Medicinal Products for Human Use (CHMP) Questions and answers on post approval change management protocols Draft agreed by CHMP / CVMP Quality
More informationMarketing authorisations granted in March 2016
PL 10321/0204 01/03/2016 RESOLUTION CHEMICALS LIMITED HYDROCORTISONE 10 MG TABLETS HYDROCORTISONE 10.00 MILLIGRAMMES POM PL 10321/0205 01/03/2016 RESOLUTION CHEMICALS LIMITED HYDROCORTISONE 20 MG TABLETS
More informationQuestions and answers relating to Restricted tender procedure EMA/2012/19/IS Provision of Security Consultancy Services
30 October 2012 EMA/702274/2012 Questions and answers relating to Restricted tender procedure EMA/2012/19/IS Provision of Security Consultancy Services Table of contents Questions and answers... 2 Document
More informationEnd of consultation (deadline for comments) 14 October 2009. Adoption by Committee for advanced therapies 15 October 2010
15 October 2010 EMA/CAT/418458/2008/corr. Committee for advanced therapies (CAT) Procedural advice on the certification of quality and nonclinical data for small and medium sized enterprises developing
More informationPOST-AUTHORISATION GUIDANCE. Human Medicinal Products
European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use London, 23 February 2006 Doc. Ref. EMEA/180079/2005 POST-AUTHORISATION GUIDANCE Human Medicinal Products QUESTIONS AND
More informationWork instructions. 1. Changes since last revision. 2. Records. 3. Instructions EXPLANATORY NOTES
Work instructions Title: Calculation of fees for GMP and product related inspections Applies to: P-CI-MQC staff Status: PUBLIC Document no.: WIN/INSP/2043 Lead Author Approver Effective Date: 13-APR-12
More informationDistant/virtual pharmacovigilance inspections of MAHs during a crisis situation- Points to consider
18 January 2013 EMA/INS/119905/2012 Compliance and Inspection Distant/virtual pharmacovigilance inspections of MAHs during a crisis situation- Points This document is intended to provide guidance on the
More informationHow to search the EU Clinical Trials Register
28 April 2014 Information and Communications Technology Contents Contents... 1 1. Searching the EU Clinical Trials Register... 1 1.1. Basic search... 2 1.2. Search for multiple words (AND operator)...
More informationAnnex VI Service Level Agreement for Medical Service Provider
Annex VI Service Level Agreement for Medical Service Provider The term medical service provider referred to in this document is the contractor with which the Agencies i.e. EMA, EBA and CEPOL have signed
More informationBiggest Launches 2014
Biggest Launches 2014 The recent staggering performance of the biotech industry has been built around a belief that the sector s R&D productivity is on the rebound and will deliver huge investor returns
More informationQuestions and answers relating to Open Procedure EMA 2012-37-ED Online Strategy and Interface Design
27 June 2013 EMA/352562/2013 Questions and answers relating to Open Procedure EMA 2012-37-ED Online Strategy and Interface Design Table of contents Questions and answers... 2 Document history... 6 7 Westferry
More informationSubmission of comments on 'Policy 0070 on publication and access to clinical-trial data'
EMA/240810/2013 Submission of comments on 'Policy 0070 on publication and access to clinical-trial data' s from: Name and affiliation For the Austrian Medicines & Medical Devices Agency (AGES), Austria,
More informationThe European regulatory system for medicines and the European Medicines Agency
The European regulatory system for medicines and the European Medicines Agency A consistent approach to medicines regulation across the European Union An agency of the European Union This booklet is intended
More informationUsing the WHO Drug Dictionary for Reporting Clinical Trials MWSUG 2007 Meeting Thomas E Peppard, decode Genetics, Brighton, MI
Paper S6-2007 Using the WHO Drug Dictionary for Reporting Clinical Trials MWSUG 2007 Meeting Thomas E Peppard, decode Genetics, Brighton, MI ABSTRACT This paper will introduce the application of the WHO
More informationXML Conversion Utility User Awareness
8 March 2011 Topics Prerequisites What you do Know Issues Prerequisites: Note: EudraCT Version 8 has a more comprehensive set of field validation to ensure data completeness and consistency that EudraCT
More informationReflection paper on clinical aspects related to tissue engineered products
1 2 3 19 March 2012 EMA/CAT/CPWP/573420/2009 Committee for Advanced Therapies (CAT) 4 5 6 Reflection paper on clinical aspects related to tissue engineered products Draft Draft agreed by CPWP 7 October
More informationRobert Ancuceanu for his exceptional work as he has resigned from the Committee and adopted the following opinions:
News from the EMA Activities of the PDCO During its meeting from 10-12 November 2010 the Paediatric Committee (PDCO) thanked Robert Ancuceanu for his exceptional work as he has resigned from the Committee
More informationCompilation of Community Procedures on Inspections and Exchange of Information
EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE- GENERAL Public Health and Risk Assessment Pharmaceuticals 27 June 2013 EMA/385898/2013 Rev 16 Compliance and Inspection Compilation of Community
More informationQuestions and answers relating to Open Tender EMA/2012/21/IS
12 December 2012 EMA/748793/2012 Table of contents Questions and answers... 2 Document history... 7 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom Telephone +44 (0)20 7418 8400 Facsimile
More informationStandard operating procedure
Standard operating procedure Title: Review and revision of effective standard operating procedures Status: PUBLIC Document no.: SOP/EMA/0013 Approver Effective date: 10-Jul-13 Name: Mario Benetti Name:
More informationWorkshop on multiple sclerosis
7 October 2013 EMA/263897/2013 Scientific and Regulatory Management Department Final programme 17 October 2013 European Medicines Agency, London, United Kingdom Room 2A 7 Westferry Circus Canary Wharf
More informationSPECIAL AUTHORIZATION GUIDELINES
91B ALBERTA DRUG BENEFIT LIST SPECIAL AUTHORIZATION GUIDELINES 37BSpecial Authorization Policy 90BDrug Products Eligible for Consideration by Special Authorization Drug Products may be considered for coverage
More informationAnatomical Therapeutic Chemical (ATC) classification and the Defined Daily Dose (DDD): principles for classifying and quantifying drug use
Anatomical Therapeutic Chemical (ATC) classification and the Defined Daily Dose (DDD): principles for classifying and quantifying drug use DRAFT Yong Chen Merck, Whitehouse Station, NJ USA Disclosure Author
More informationReflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials
1 2 3 5 August 2011 EMA/INS/GCP/600788/2011 Compliance and Inspection 4 5 6 7 Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials
More informationSTEM CELL FELLOWSHIP
Module I: The Basic Principles of Stem Cells 1. Basics of Stem Cells a. Understanding the development of embryonic stem cells i. Embryonic stem cells ii. Embryonic germ cells iii. Differentiated stem cell
More informationEnabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV
Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Maria Isaac, MASc, MD, PhD, MFPM, Psychiatrist Senior Scientific Officer Institute
More informationClinical Trials Register
Page 1 of 10 EU-CTR Version: 1.1.1 EU Clinical Trials Register Search for Clinical Trials Home Search About Glossary Data Quality Joining a trial Contacts EudraPharm Clinicaltrialsregister.eu Summary EudraCT
More informationSubmission of comments on 'Policy 0070 on publication and access to clinical-trial data'
EMA/240810/2013 Submission of comments on 'Policy 0070 on publication and access to clinical-trial data' s from: Name and affiliation PHARMIG - Association of the Austrian pharmaceutical industry Please
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)
European Medicines Agency Veterinary Medicines and Inspections London, 15 April 2005 EMEA/CVMP/134/02 Rev 1 CPMP/QWP/227/02 Rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
London, 22 October 2009 Doc. Ref. EMEA/CHMP/EWP/692702/2008 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) REFLECTION PAPER ON THE EXTRAPOLATION OF RESULTS FROM CLINICAL STUDIES CONDUCTED OUTSIDE
More informationThe Cell Therapy Catapult UK Clinical Trials Database
May 2015 The UK Clinical Trials Database covers cell therapy clinical trial activity that the Cell Therapy Catapult believes to be ongoing in the UK as of May 2015. It supersedes the database of April
More informationHybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs
Hybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs Drug Information Journal 00(0) 1-6 ª The Author(s) 2012
More informationNEW DRUG APPROVALS IN ICH COUNTRIES 2004 2013 FOCUS ON 2013
24 24 24 Approval time (days) Approval time (years) NEW DRUG APPROVALS IN ICH COUNTRIES 24 FOCUS ON Median 25 th and 75 th percentile 12 1 8 6 NASs approval time by approval year 24- Median; 25 th and
More informationBiological. Medicines. A Focus on Biosimilar. Medicines
TM Biological Medicines TM EuropaBio is the voice of the European biotech Industry. It represents the interests of the industry towards the European institutions so that legislation encourages and enables
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 19 July 2007 Doc. Ref: EMEA/27170/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON COMPASSIONATE USE OF MEDICINAL
More informationClinical trials submitted in marketing-authorisation applications to the European Medicines Agency
11 December 2013 EMA/INS/GCP/676319/2012 Compliance and Inspection Clinical trials submitted in marketing-authorisation applications to the European Medicines Agency Overview of patient recruitment and
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) REFLECTION PAPER
European Medicines Agency London 23 April 2009 EMEA/CHMP/BMWP/102046/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) REFLECTION PAPER NON-CLINICAL AND CLINICAL DEVELOPMENT OF SIMILAR MEDICINAL
More informationGuidance for the format and content of the protocol of non-interventional post-authorisation safety studies
26 September 2012 EMA/623947/2012 Patient Health Protection Guidance for the format and content of the protocol of non-interventional post-authorisation Introduction From 10 January 2013, marketing authorisation
More informationGuideline on similar biological medicinal products containing interferon beta
21 February 2013 EMA/CHMP/BMWP/652000/2010 Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing interferon beta Draft Agreed by BMWP June
More informationAllgemeine Rahmenbedingungen für die Entwicklung und Zulassung von Orphan Medicinal Products
Allgemeine Rahmenbedingungen für die Entwicklung und Zulassung von Orphan Medicinal Products PMS-Workshop Arzneimitteltherapie seltener Krankheiten Herausforderungen und Chancen Berlin-Brandenburgische
More informationEMEA PUBLIC STATEMENT ON LEFLUNOMIDE (ARAVA) - SEVERE AND SERIOUS HEPATIC REACTIONS -
The European Agency for the Evaluation of Medicinal Products Post-authorisation evaluation of medicines for human use London, 12 March 2001 Doc. Ref: EMEA/H/5611/01/en EMEA PUBLIC STATEMENT ON LEFLUNOMIDE
More informationGuideline on similar biological medicinal products containing interferon beta
1 2 3 15 December 2011 EMA/CHMP/BMWP/652000/2010 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on similar biological medicinal products containing interferon beta 7 Draft Draft
More informationEisen en Verplichtingen
Registratie ti van Biosimilars: i il Eisen en Verplichtingen Dr. Thijs J. Giezen Ziekenhuisapotheker, Stichting Apotheek Haarlemse Ziekenhuizen Lid, CHMP Biosimilar Working Party (BMWP), European Medicines
More informationGuideline on stability testing for applications for variations to a marketing authorisation
21 March 2014 EMA/CHMP/CVMP/QWP/441071/2011- Rev.2 Committee for Medicinal Products for Human Use (CHMP)/ Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on stability testing for applications
More informationFULL DESCRIPTION OF QUARTERWATCH METHODOLOGY
FULL DESCRIPTION OF QUARTERWATCH METHODOLOGY The FDA s Adverse Event Reporting System (AERS) data present numerous challenges to systematic analysis as presented in QuarterWatch. We summarize the fundamentals
More informationProducts for which the marketing authorisations are recommended for suspension by the CHMP on 21 May 2015
21 May 2015 EMA/344050/2015 Procedure Management and Committee Support Products for which the marketing authorisations are recommended for suspension by the CHMP on 21 May 2015 Article 31 of Directive
More informationEuropean Medicines Agency recommends restricting use of trimetazidine-containing medicines
22 June 2012 EMA/CHMP/417861/2012 Press Office Press release European Medicines Agency recommends restricting use of trimetazidine-containing medicines Restricted indication for patients with stable angina
More informationCompilation of individual product-specific guidance on demonstration of bioequivalence
17 December 2014 EMA/CHMP/736403/2014 Committee for Medicinal Products for Human Use (CHMP) Compilation of individual product-specific guidance on demonstration of bioequivalence Initial batch of individual
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA Brussels, 27.03.2014 ENTR/6283/00 Rev 4 orphan\guidelines\format content
More informationQRD recommendations on pack design and labelling for centrally authorised non-prescription human medicinal products
1 2 3 10 March 2011 Quality Review Documents (QRD) 4 5 6 7 QRD recommendations on pack design and labelling for centrally authorised non-prescription human medicinal products Draft Draft Agreed by Quality
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 17 July 2006 Doc. Ref. EMEA/419127/05 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PROCEDURE
More informationGuideline on Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs)
London, 21 April 2009 Doc. Ref. EMA/13432/2009 Committee for Medicinal Products for Human Use (CHMP) Guideline on Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports
More informationOrphan Development - Allogeneic Human Umbilical Cord Tissue
9 June 2010 EMA/COMP/48111/2008 Rev.1 Committee for Orphan Medicinal Products allogeneic human umbilical cord tissue-derived cells for treatment of retinitis pigmentosa Please note that this product was
More informationPPRS 2014 analysis of growth in spend of branded medicines. DH Leading the nation s health and care
PPRS 2014 analysis of growth in spend of branded medicines March 2015 Executive Summary IMS Health data shows growth in spend in 2014 (compared to 2013) of 8.2% on branded medicines. This is higher than
More informationQuestions and answers on serious non-fatal adverse events and reporting rules
18 April 2013 EMA/CVMP/PhVWP/303762/2012 Committee for Medicinal Products for Veterinary Use Questions and answers on serious non-fatal adverse events and reporting rules This question and answer document
More informationEU Clinical Trials Register
EU Clinical Trials Register Disclaimer: The explanations are provided for the benefit of public users of the system and to enhance general understanding of terms used. They are not intended as the regulatory
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 10 October 2007 Doc. Ref. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON POTENCY TESTING OF CELL BASED IMMUNOTHERAPY
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES
More informationCommunity herbal monograph on Commiphora molmol Engler, gummi-resina
12 July 2011 EMA/HMPC/96911/2010 Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Commiphora molmol Engler, gummi-resina Final Discussion in Working Party on Community monographs
More informationQuick Response (QR) codes in the labelling and package leaflet of centrally authorised 1 medicinal products
22 July 2015 EMA/493897/2015 Human Medicines Evaluation Division Quick Response (QR) codes in the labelling and package leaflet of centrally authorised 1 medicinal General principles of acceptability and
More informationGuideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision)
18 March 2010 EMEA/CHMP/BMWP/301636/2008 Corr.* Committee for Medicinal Products for Human Use (CHMP) Guideline on non-clinical and clinical development of similar biological medicinal products containing
More informationGuideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues
1 2 3 03 June May 2013 EMEA/CHMP/BMWP/42832/2005 Rev. 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on similar biological medicinal products containing biotechnology-derived
More informationPlease note that this draft Annex I may be updated to reflect further information on concerned products/mahs
2 May 2016 EMA/314147/2016 Corr. 7 Procedure Management and Committees Support Annex I List of the names, pharmaceutical s, strengths of the medicinal products, routes of, marketing authorisat s in the
More informationNovel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?
Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International
More informationReflection Paper on Medicinal Product Supply Shortages Caused by Manufacturing/GMP Compliance Problems
14 September 2012 /590745/2012 Patient Health Protection Reflection Paper on Medicinal Product Supply Shortages Caused by Manufacturing/GMP 1. Introduction Ensuring the security and Good Manufacturing
More informationBiosimilars Demystified
Biosimilars Demystified Thijs J. Giezen, PhD, PharmD, MSc Hospital Pharmacist, Foundation Pharmacy for Hospitals in Haarlem Member Biosimilar Working Party, European Medicines Agency I attend this conference
More information2015-10-26 10:58 FOR UK AND EMEA MEDICAL MEDIA ONLY. (Logo: http://photos.prnewswire.com/prnh/20140324/ny88746logo)
2015-10-26 10:58 Janssen Receives Positive CHMP Opinion Recommending EDURANT(R)Black Triangle Drug (rilpivirine) for the Treatment of Adolescents Aged 12 to
More informationIllinois Department of Revenue Regulations TITLE 86: REVENUE CHAPTER I: DEPARTMENT OF REVENUE
Illinois Department of Revenue Regulations Title 86 Part 530 Section 530.110 Covered Prescription Drugs TITLE 86: REVENUE CHAPTER I: DEPARTMENT OF REVENUE PART 530 SENIOR CITIZENS AND DISABLED PERSONS
More information1. What has a higher stored energy potential per gram, glycogen or triglycerides? Explain.
Lipid Metabolism 1. What has a higher stored energy potential per gram, glycogen or triglycerides? Explain. 2. How can excess acetyl CoA trapped in the mitochondria, be utilized as a substrate for fatty
More informationCommunity herbal monograph on Cucurbita pepo L., semen
20 November 2012 EMA/HMPC/136024/2010 Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Cucurbita pepo L., semen Final Discussion in Working Party on Community monographs and
More informationAdoption by GCP Inspectors Working Group for consultation 14 June 2011. End of consultation (deadline for comments) 15 February 2012
10 December 2013 EMA/INS/GCP/600788/2011 Compliance and Inspection Reflection paper on the use of interactive response technologies (interactive voice/web response systems) in clinical trials, with particular
More informationHow To Follow Up After Treatment With Gene Therapy
European Medicines Agency London, 30 May 2008 Doc. Ref. EMEA/CHMP/GTWP/60436/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON FOLLOW-UP OF PATIENTS ADMINISTERED WITH GENE THERAPY
More informationTherapeutic Goods Administration Orphan Drugs Program: Discussion paper
Therapeutic Goods Administration Orphan Drugs Program: Discussion paper Submission from the Clinical Oncology Society of Australia and Cancer Council Australia March 2015 The Clinical Oncology Society
More informationDRUGS BILLED UNDER MISCELLANEOUS CODES J3490, J3590, J9999 OR C9399 COVERAGE INFORMATION
ACTEMRA (toclizumab) 10/21/13 ADASUVE (loxapine aerosol powder breath activated) 01/24/14 ADDAMEL N INJ (Trace Min (CR-CU-F-FE-I-MN-MO-SE-ZN) INJ) 05/20/13 ADYNOVATE (Antihemophilic Factor Recomb Pegylated
More informationII. AREA OF INVOLVEMENT OF PATIENTS AND CONSUMERS IN EMEA ACTIVITIES
European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use MINUTES OF THE EIGHTH MEETING OF THE EMEA HUMAN SCIENTIFIC COMMITTEES WORKING PARTY WITH PATIENTS' AND CONSUMERS' ORGANISATIONS
More informationMalignant Mesothelioma - Pipeline Review, H1 2015
Brochure More information from http://www.researchandmarkets.com/reports/3308784/ Malignant Mesothelioma - Pipeline Review, H1 2015 Description: Malignant Mesothelioma - Pipeline Review, H1 2015 Summary
More informationOrphan drugs program. Discussion paper. May 2015
Orphan drugs program Discussion paper About the Therapeutic Goods Administration (TGA) The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible
More informationStrategy and pilot phase for patient registries
Strategy and pilot phase for patient registries Draft still under discussion Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015 Xavier Kurz, Head of Monitoring
More information